サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467741

オンコロジー向けバイオシミラー市場レポート：薬剤タイプ、がんタイプ、流通チャネル、地域別、2024～2032年

Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 135 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
オンコロジー向けバイオシミラー市場レポート：薬剤タイプ、がんタイプ、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

オンコロジー向けバイオシミラーの世界市場規模は2023年に47億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて22.3%の成長率（CAGR）を示し、2032年までに303億米ドルに達すると予測しています。

がんは、細胞の異常増殖によって発生する生活習慣病であり、腫瘍が形成されることもあります。現在、効果的ながん治療のほとんどは、生物学的製剤とも呼ばれる生物学的薬剤に基づいており、免疫療法だけでなく標的療法も含まれます。これらの薬剤は、細菌、酵母、動植物細胞などの生体を用いて製造されるため、複雑な製造工程と長い開発期間を必要とします。その結果、これらの薬剤のコストは相対的に高くなり、がん治療の出費に拍車をかけています。治療費を下げるために、先発品のがん生物学的製剤のバイオシミラーの開発への関心が高まっています。これらのバイオシミラーは、有効性と安全性の点で参照生物学的製剤と非常に類似しており、低コストであるため、がん治療費の大幅な削減に役立ちます。

長年にわたり、高齢者人口の増加や環境の悪化により、世界中でがんの有病率が増加しています。これらの要因は、がん治療費の高騰とともに、世界中の医療システムの負担を増大させています。そのため、各国の当局はコスト抑制策としてバイオシミラーの導入を推進しています。例えば、米国食品医薬品局（USFDA）は、バイオシミラーについて医師や患者を教育するための情報資料を作成しました。これとは別に、手頃な価格の医薬品が入手可能になることは、患者アクセスの改善だけでなく、治療の早期化・拡大にもつながっています。これに加えて、オンコロジー向けバイオシミラー医薬品は業界の競合を激化させ、生物学的製剤の価格をさらに引き下げる可能性があります。その他の市場開拓要因としては、ブランド生物製剤の特許切れが近づいていること、バイオシミラーメーカーの研究開発活動が活発化していることなどが挙げられます。

本レポートで扱う主要質問

  • 世界のオンコロジー向けバイオシミラー市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界のオンコロジー向けバイオシミラー産業に与えた影響は？
  • 世界のオンコロジー向けバイオシミラー産業における主要地域市場は？
  • 薬剤タイプ別の市場内訳は？
  • がんタイプ別の市場内訳は？
  • 販売チャネル別の市場内訳は？
  • 世界のオンコロジー向けバイオシミラー産業のバリューチェーンにおける様々な段階とは？
  • 世界のオンコロジー向けバイオシミラー産業の主要促進要因と課題は何か？
  • 世界のオンコロジー向けバイオシミラー産業の構造と主要参入企業は？
  • 世界のオンコロジー向けバイオシミラー業界における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 オンコロジー向けバイオシミラーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：薬剤タイプ別
  • 市場内訳：がんタイプ別
  • 市場内訳：流通チャネル別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • モノクローナル抗体
  • 免疫調節薬
  • G-CSF製剤
  • 造血剤
  • その他

第7章 市場内訳：がんタイプ別

  • 肺がん
  • 大腸がん
  • 子宮頸がん
  • 乳がん
  • 腎臓がん
  • 胃がん
  • 脳腫瘍
  • その他

第8章 市場内訳：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • その他

第9章 市場内訳：地域別

  • 欧州
  • アジア太平洋
  • 北米
  • 中東・アフリカ
  • ラテンアメリカ

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Biocon Limited
    • Celltrion Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Intas Pharmaceuticals Ltd.
    • STADA Arzneimittel AG
    • Pfizer Inc.
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • BIOCAD Biotechnology Company
    • Mylan N.V.
    • F. Hoffmann-La Roche AG
図表

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players
目次
Product Code: SR112024A1572

The global oncology biosimilars market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.3 Billion by 2032, exhibiting a growth rate (CAGR) of 22.3% during 2024-2032.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

Monoclonal Antibody

Immunomodulators

G-CSF

Hematopoietic Agents

Others

Breakup by Cancer Type:

Lung Cancer

Colorectal Cancer

Cervical Cancer

Breast Cancer

Kidney Cancer

Stomach Cancer

Brain Cancer

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Others

Breakup by Region:

Europe

Asia Pacific

North America

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology biosimilars industry?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Cancer Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibody
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunomodulators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 G-CSF
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Hematopoietic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Colorectal Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cervical Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Breast Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Stomach Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Brain Cancer
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocon Limited
    • 14.3.2 Celltrion Inc.
    • 14.3.3 Dr. Reddy's Laboratories Ltd.
    • 14.3.4 Intas Pharmaceuticals Ltd.
    • 14.3.5 STADA Arzneimittel AG
    • 14.3.6 Pfizer Inc.
    • 14.3.7 Apotex Inc.
    • 14.3.8 Teva Pharmaceutical Industries Ltd.
    • 14.3.9 Sandoz International GmbH
    • 14.3.10 BIOCAD Biotechnology Company
    • 14.3.11 Mylan N.V.
    • 14.3.12 F. Hoffmann-La Roche AG